Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients

Windy Berkofsky-Fessler, Tri Q. Nguyen, Paul Delmar, Juliette Molnos, Charu Kanwal, Wanda DePinto, James Rosinski, Patricia McLoughlin, Steve Ritland, Mark DeMario, Krishna Tobon, John F. Reidhaar-Olson, Ruediger Rueger, Holly Hilton

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

A genomics-based approach to identify pharmacodynamic biomarkers was used for a cyclin-dependent kinase inhibitory drug. R547 is a potent cyclin-dependent kinase inhibitor with a potent antiproliferative effect at pharmacologically relevant doses and is currently in phase I clinical trials. Using preclinical data derived from microarray experiments,we identified pharmacodynamic biomarkers to test in blood samples from patients in clinical trials. These candidate biomarkers were chosen based on several criteria: relevance to the mechanism of action of R547, dose responsiveness in preclinical models, and measurable expression in blood samples. We identified 26 potential biomarkers of R547 action and tested their clinical validity in patient blood samples by quantitative real-time PCR analysis. Based on the results, eight genes (FLJ44342, CD86, EGR1, MKI67, CCNB1, JUN, HEXIM1, and PFAAP5) were selected as dose-responsive pharmacodynamic biomarkers for phase II clinical trials.

Original languageEnglish (US)
Pages (from-to)2517-2525
Number of pages9
JournalMolecular Cancer Therapeutics
Volume8
Issue number9
DOIs
StatePublished - Sep 1 2009
Externally publishedYes

Fingerprint

Cyclin-Dependent Kinases
Biomarkers
Phase II Clinical Trials
Clinical Trials, Phase I
Hematologic Tests
Genomics
Real-Time Polymerase Chain Reaction
Clinical Trials
Pharmaceutical Preparations
Genes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients. / Berkofsky-Fessler, Windy; Nguyen, Tri Q.; Delmar, Paul; Molnos, Juliette; Kanwal, Charu; DePinto, Wanda; Rosinski, James; McLoughlin, Patricia; Ritland, Steve; DeMario, Mark; Tobon, Krishna; Reidhaar-Olson, John F.; Rueger, Ruediger; Hilton, Holly.

In: Molecular Cancer Therapeutics, Vol. 8, No. 9, 01.09.2009, p. 2517-2525.

Research output: Contribution to journalArticle

Berkofsky-Fessler, W, Nguyen, TQ, Delmar, P, Molnos, J, Kanwal, C, DePinto, W, Rosinski, J, McLoughlin, P, Ritland, S, DeMario, M, Tobon, K, Reidhaar-Olson, JF, Rueger, R & Hilton, H 2009, 'Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients', Molecular Cancer Therapeutics, vol. 8, no. 9, pp. 2517-2525. https://doi.org/10.1158/1535-7163.MCT-09-0083
Berkofsky-Fessler, Windy ; Nguyen, Tri Q. ; Delmar, Paul ; Molnos, Juliette ; Kanwal, Charu ; DePinto, Wanda ; Rosinski, James ; McLoughlin, Patricia ; Ritland, Steve ; DeMario, Mark ; Tobon, Krishna ; Reidhaar-Olson, John F. ; Rueger, Ruediger ; Hilton, Holly. / Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients. In: Molecular Cancer Therapeutics. 2009 ; Vol. 8, No. 9. pp. 2517-2525.
@article{f0b1068fb85a49af940f87058316b6e6,
title = "Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients",
abstract = "A genomics-based approach to identify pharmacodynamic biomarkers was used for a cyclin-dependent kinase inhibitory drug. R547 is a potent cyclin-dependent kinase inhibitor with a potent antiproliferative effect at pharmacologically relevant doses and is currently in phase I clinical trials. Using preclinical data derived from microarray experiments,we identified pharmacodynamic biomarkers to test in blood samples from patients in clinical trials. These candidate biomarkers were chosen based on several criteria: relevance to the mechanism of action of R547, dose responsiveness in preclinical models, and measurable expression in blood samples. We identified 26 potential biomarkers of R547 action and tested their clinical validity in patient blood samples by quantitative real-time PCR analysis. Based on the results, eight genes (FLJ44342, CD86, EGR1, MKI67, CCNB1, JUN, HEXIM1, and PFAAP5) were selected as dose-responsive pharmacodynamic biomarkers for phase II clinical trials.",
author = "Windy Berkofsky-Fessler and Nguyen, {Tri Q.} and Paul Delmar and Juliette Molnos and Charu Kanwal and Wanda DePinto and James Rosinski and Patricia McLoughlin and Steve Ritland and Mark DeMario and Krishna Tobon and Reidhaar-Olson, {John F.} and Ruediger Rueger and Holly Hilton",
year = "2009",
month = "9",
day = "1",
doi = "10.1158/1535-7163.MCT-09-0083",
language = "English (US)",
volume = "8",
pages = "2517--2525",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients

AU - Berkofsky-Fessler, Windy

AU - Nguyen, Tri Q.

AU - Delmar, Paul

AU - Molnos, Juliette

AU - Kanwal, Charu

AU - DePinto, Wanda

AU - Rosinski, James

AU - McLoughlin, Patricia

AU - Ritland, Steve

AU - DeMario, Mark

AU - Tobon, Krishna

AU - Reidhaar-Olson, John F.

AU - Rueger, Ruediger

AU - Hilton, Holly

PY - 2009/9/1

Y1 - 2009/9/1

N2 - A genomics-based approach to identify pharmacodynamic biomarkers was used for a cyclin-dependent kinase inhibitory drug. R547 is a potent cyclin-dependent kinase inhibitor with a potent antiproliferative effect at pharmacologically relevant doses and is currently in phase I clinical trials. Using preclinical data derived from microarray experiments,we identified pharmacodynamic biomarkers to test in blood samples from patients in clinical trials. These candidate biomarkers were chosen based on several criteria: relevance to the mechanism of action of R547, dose responsiveness in preclinical models, and measurable expression in blood samples. We identified 26 potential biomarkers of R547 action and tested their clinical validity in patient blood samples by quantitative real-time PCR analysis. Based on the results, eight genes (FLJ44342, CD86, EGR1, MKI67, CCNB1, JUN, HEXIM1, and PFAAP5) were selected as dose-responsive pharmacodynamic biomarkers for phase II clinical trials.

AB - A genomics-based approach to identify pharmacodynamic biomarkers was used for a cyclin-dependent kinase inhibitory drug. R547 is a potent cyclin-dependent kinase inhibitor with a potent antiproliferative effect at pharmacologically relevant doses and is currently in phase I clinical trials. Using preclinical data derived from microarray experiments,we identified pharmacodynamic biomarkers to test in blood samples from patients in clinical trials. These candidate biomarkers were chosen based on several criteria: relevance to the mechanism of action of R547, dose responsiveness in preclinical models, and measurable expression in blood samples. We identified 26 potential biomarkers of R547 action and tested their clinical validity in patient blood samples by quantitative real-time PCR analysis. Based on the results, eight genes (FLJ44342, CD86, EGR1, MKI67, CCNB1, JUN, HEXIM1, and PFAAP5) were selected as dose-responsive pharmacodynamic biomarkers for phase II clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=70349499021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349499021&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-09-0083

DO - 10.1158/1535-7163.MCT-09-0083

M3 - Article

C2 - 19755512

AN - SCOPUS:70349499021

VL - 8

SP - 2517

EP - 2525

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 9

ER -